ATOVAQUONE AND NRTIS
Atovaquone inhibits the glucuronidation of zidovudine, but this only resulted in a small 25% decrease in its clearance in one study, and no significant pharmacokinetic changes in another.
The increased plasma levels of zidovudine are unlikely to be clinically significant. Nevertheless, the manufacturers recommend regular monitoring for zidovudine- associated adverse effects, particularly if atovaquone suspension is used, as this achieves higher atovaquone levels.
The increased plasma levels of zidovudine are unlikely to be clinically significant. Nevertheless, the manufacturers recommend regular monitoring for zidovudine- associated adverse effects, particularly if atovaquone suspension is used, as this achieves higher atovaquone levels.